Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Hazem Abosheaishaa: Beta-Blocker Selection Matters – Multi-Institutional Cohort Insights on PVT and Survival in Cirrhosis
Hazem Abosheaishaa/LinkedIn
Sep 5, 2026, 16:16

Hazem Abosheaishaa: Beta-Blocker Selection Matters – Multi-Institutional Cohort Insights on PVT and Survival in Cirrhosis

Hazem Abosheaishaa, GI Fellow at TBHC, Former IM chief Resident at ISMMS Queens, shared a post on X about a recent article he and his colleagues co-authored, published in Liver International, adding:

“New study by the team GiResearchClub in Liver International:

Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta-Blockers: A Multi-Institutional Cohort Study Do all nonselective β-blockers carry the same risk in cirrhosis?

In our large multi-institutional cohort:

  • Propranolol – high portal vein thrombosis risk
  • Carvedilol – no increased PVT risk
  • Carvedilol – improved survival

These findings highlight that β-blocker selection may meaningfully influence outcomes in cirrhosis.”

Title: Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta-Blockers: A Multi-Institutional Cohort Study

Authors: Hazem Abosheaishaa, Khaled Elfert, Mohammed Abusuliman, Abdellatif Ismail, Abdullah Olimy, Ahmed Elsayed Alzamzamy, Ahmed Omran, Vincent Rizzo, Mahmoud Nassar, Mohamed El-Kassas

Hazem Abosheaishaa

Stay updated on all scientific advances with Hemostasis Today.

Abdellatif Ismail Abdullah Olimy Ahmed Elsayed Alzamzamy Ahmed Omran Carvedilol GiResearchClub Hazem Abosheaishaa Health Hematology Hemostasis Hemostasis News Hemostasis Today Khaled Elfert Liver International Mahmoud Nassar Medicine Mohamed El-Kassas Mohammed Abusuliman Propranolol Vincent Rizzo
NewsFeed